Is Tango Therapeutics, Inc. overvalued or undervalued?

As of 9 August 2021, the valuation grade for Tango Therapeutics, Inc. has moved from does not qualify to risky, indicating increased scrutiny on its financial metrics. The company appears to be overvalued given its negative P/E ratio and troubling financial ratios, including a Price to Book Value of 2.77 and an EV to Sales ratio of 6.04. Additionally, the Return on Equity (ROE) stands at an alarming -79.32%, highlighting significant inefficiencies in generating profit from equity.
In comparison to its peers, Tango Therapeutics, Inc. has a P/E ratio of -3.94, while ANI Pharmaceuticals, Inc. also classified as risky, shows a much worse P/E of -100.77. On the other hand, Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 18.69, suggesting that Tango is not only overvalued but also underperforming relative to healthier competitors. Despite a recent strong performance against the S&P 500, with a 1-month return of 189.13% compared to 3.83% for the index, the underlying financials suggest that the stock is not justified at its current price level.